文献速递核素与放射性配体治疗

177Lu-OncoFAP-23(一种多价FAP靶向放射性药物治疗剂)用于实体瘤的临床前评价

Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors.
PubMed 文献 · J Nucl Med · 2024-10-01

研究在荷瘤小鼠中评价了177Lu-OncoFAP-23的组织生物分布与治疗效果,并与177Lu-OncoFAP和177Lu-FAP-2286对照。177Lu-OncoFAP-23显示高且持久的肿瘤摄取(96小时约16%注射剂量/克)和低健康器官蓄积,联合L19-IL2可增强抗肿瘤活性。数据支持177Lu-OncoFAP-23用于FAP阳性实体瘤的临床开发。

要点

  • 177Lu-OncoFAP-23在荷瘤小鼠中显示高且持久的肿瘤摄取(96小时约16%注射剂量/克)和低健康器官蓄积。
  • 177Lu-OncoFAP-23单药在低给药放射性水平下即显示强效抗肿瘤活性,联合L19-IL2可进一步拓宽治疗窗。
  • OncoFAP-23和natLu-OncoFAP-23在高剂量下未显示副作用或毒性征象。

核心结论

  • OncoFAP-23具有增强的肿瘤摄取和肿瘤滞留以及低健康器官蓄积,对应体内抗肿瘤疗效的显著改善。
  • 本研究数据支持177Lu-OncoFAP-23用于FAP阳性实体瘤治疗的临床开发。

研究设计与样本

  • 临床前研究:OncoFAP-23用治疗诊断核素177Lu标记。
  • 在荷SK-RC-52.hFAP肿瘤的BALB/c裸鼠或荷CT-26.hFAP肿瘤的BALB/c小鼠中进行实验。
  • 生物分布研究纳入177Lu-OncoFAP和177Lu-FAP-2286作为对照。
  • 毒理学评价在Wistar大鼠和CD1小鼠中分别注射高剂量OncoFAP-23或其冷标记对应物进行。

主要发现

  • 177Lu-OncoFAP-23显示最佳类生物分布特征,高且持久的肿瘤摄取(96小时约16%注射剂量/克),健康器官蓄积低。
  • 177Lu-OncoFAP-23在低给药放射性水平下显示强效单药抗肿瘤活性。
  • 与肿瘤靶向白细胞介素2(L19-IL2,临床阶段免疫细胞因子)联合治疗通过增强体内抗肿瘤活性进一步拓宽177Lu-OncoFAP-23的治疗窗。
  • 蛋白质组学研究显示联合治疗时产生强效肿瘤定向免疫应答。
  • OncoFAP-23和natLu-OncoFAP-23显示有利的毒理学特征,未显示任何副作用或毒性征象。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Fibroblast activation protein (FAP) is abundantly expressed in the stroma of most human solid tumors. Clinical-stage radiolabeled FAP ligands are increasingly used as tools for the detection of various cancer lesions. To unleash the full therapeutic potential of FAP-targeting agents, ligands need to remain at the tumor site for several days after administration. We recently described the discovery of OncoFAP, a high-affinity small organic ligand of FAP with a rapid accumulation in tumors and low uptake in healthy tissues in cancer patients. Trimerization of OncoFAP provided a derivative (named TriOncoFAP, or OncoFAP-23) with improved FAP affinity. In this work, we evaluated the tissue biodistribution profile and the therapeutic performance of OncoFAP-23 in tumor-bearing mice. Methods: OncoFAP-23 was radiolabeled with the theranostic radionuclide 177Lu. Preclinical experiments were conducted on mice bearing SK-RC-52.hFAP (BALB/c nude mice) or CT-26.hFAP (BALB/c mice) tumors. 177Lu-OncoFAP and 177Lu-FAP-2286 were included in the biodistribution study as controls. Toxicologic evaluation was performed on Wistar rats and CD1 mice by injecting high doses of OncoFAP-23 or its cold-labeled counterpart, respectively. Results: 177Lu-OncoFAP-23 emerged for its best-in-class biodistribution profile, high and prolonged tumor uptake (i.e., ∼16 percentage injected dose/g at 96 h), and low accumulation in healthy organs, which correlates well with its potent single-agent anticancer activity at low levels of administered radioactivity. Combination treatment with the tumor-targeted interleukin 2 (L19-IL2, a clinical-stage immunocytokine) further expands the therapeutic window of 177Lu-OncoFAP-23 by potentiating its in vivo antitumor activity. Proteomics studies revealed a potent tumor-directed immune response on treatment with the combination. OncoFAP-23 and natLu-OncoFAP-23 exhibited a favorable toxicologic profile, without showing any side effects or signs of toxicity. Conclusion: OncoFAP-23 presents enhanced tumor uptake and tumor retention and low accumulation in healthy organs, findings that correspond to a strongly improved in vivo antitumor efficacy. The data presented in this work support the clinical development of 177Lu-OncoFAP-23 for the treatment of FAP-positive solid tumors.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Galbiati A, Bocci M, Ravazza D, et al. Preclinical Evaluation of 177Lu-OncoFAP-23, a Multivalent FAP-Targeted Radiopharmaceutical Therapeutic for Solid Tumors. J Nucl Med. 2024. PMID: 39266289. doi:10.2967/jnumed.124.268200

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。